Session » Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

Abstract Number: 2035

Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis

Abstract Number: 2036

Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis

Abstract Number: 2037

CTLA4 Signaling Down-Regulates Fcγ Receptor I Expression on Circulating Monocytes: A Potential Mechanism of Action of Abatacept for RA

Abstract Number: 2038

Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis

Abstract Number: 2039

A Survey of Blood and Synovial Tissue Myeloid Cells in RA Patients By Transcriptional Profiling

Abstract Number: 2040

Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.

Abstract Number: 2041

Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis

Abstract Number: 2042

Immunophenotypic Analysis of Tissue-Resident Memory T Cells in Rheumatoid Arthritis

Abstract Number: 2043

Monocytes and Macrophages of Patients with Rheumatoid Arthritis Respond to Pathologically Increased Ionized Calcium with Proinflammatory Cytokine Production

Abstract Number: 2044

Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies

Abstract Number: 2045

Specific Anti-Citrullinated Protein Antibodies Profiles Are Associated with Rheumatoid Arthritis Related Interstitial Lung Disease

Abstract Number: 2046

Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies

Abstract Number: 2047

Synovial Fluid Cytokines /Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients Which Correlate with the Magnitude of the Inflammatory Response As Measured By Synovial Fluid WBC Levels

Abstract Number: 2048

In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis

Abstract Number: 2049

Expression and Function of a Novel Citrullinated Form of Interleukin 6 in Rheumatoid Arthritis

Abstract Number: 2050

B and T Cell Phenotypes of First Degree Relatives of RA Patients in an Indigenous North American Cohort

Abstract Number: 2051

Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis

Abstract Number: 2052

Immune Therapy of Rheumatoid Arthritis Patients with a Microbiome-Derived, Self/Non-Self Peptide Induces Clinically Relevant Immune Tolerance Pivoting on Immune Checkpoint-Expressing, Therapy-Induced Tregs

Abstract Number: 2053

Global Mirna Expression and Transcriptomic Profiling of Monocytes from RA Patients

Abstract Number: 2054

In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity

Abstract Number: 2055

Laser Capture Microdissection to Interrogate B Cells in RA Synovial Tissue

Abstract Number: 2056

Citrullination Is Not a Determinant in the Lack of Tolerance to Peptidylarginine Deiminase 2 and 4 in Rheumatoid Arthritis

Abstract Number: 2057

Alterations of the Splicing Machinery in Leukocyte Subsets of Rheumatoid Arthritis Patients Modulate Their Inflammatory, Autoimmune and Atherothrombotic Profiles